Dipyrone, great killer or innocent as any drug: two case reports presenting rare and life-threatening adverse effects of dipyrone.
Dipyrone is a potent analgesic and antipyretic drug that has been used clinically for more than 80 years. In some parts of the world, it has been banned because of its association with agranulocytosis. We reported two different cases, presenting with rare but life-threatening adverse effects of dipy...
| Publicado en: | Turkiye Klinikleri Journal of Medical Sciences Vol. 32; no. 3; pp. 832 - 837 |
|---|---|
| Autores principales: | , |
| Formato: | case study Journal Article |
| Publicado: |
Turkiye Klinikleri
Jun2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104446226&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104446226 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13000292 1VOP jtl: Turkiye Klinikleri Journal of Medical Sciences issn: 13000292 maglogo: N pubinfo: dt: Jun2012 vid: 32 iid: 3 pid: 67298 pub: Turkiye Klinikleri artinfo: ui: 104446226 104446226 2011551605 10.5336/medsci.2010-18328 104446226 ppf: 832 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Dipyrone, great killer or innocent as any drug: two case reports presenting rare and life-threatening adverse effects of dipyrone. aug: au: Yigit, Özlem Soyuncu, Seçgin sug: subj: Analgesics, Nonnarcotic Adverse Effects Drug Hypersensitivity Aged Female Male Middle Age Aged: 65+ years Middle Aged: 45-64 years Female Male ab: Dipyrone is a potent analgesic and antipyretic drug that has been used clinically for more than 80 years. In some parts of the world, it has been banned because of its association with agranulocytosis. We reported two different cases, presenting with rare but life-threatening adverse effects of dipyrone. First case was a 63-year-old woman that presented to the emergency department with fever. She had developed neutropenia after taking a 500 mg oral dipyrone tablet and following further evaluation was diagnosed with dipyrone-induced agranulocytosis. Second case was a 70-year-old man who presented to the emergency department with diffuse erythematous skin rash after dipyrone injection and was diagnosed with toxic epidermal necrolysis associated with dipyrone. The balance between the benefit and harm is particularly important. Nevertheless, agranulocytosis is not the only life-threatening risk with dipyrone use and limiting the discussion of risks of dipyrone to agranulocytosis leads to an underestimation of the dangers of the drug. pubtype: Academic Journal doctype: case study Journal Article ougenre: Article language: Turkish refInfo: holdings: @attributes: islocal: N |
|---|